This market niche could change the game for Big Pharma

This could trigger a massive profit explosion (up to 1,000%)

You are receiving this as part of your free subscription to Money Morning Profit Alerts. To remove your email from this list, unsubscribe here.

Update: Today, We're Moving beyond the Borders of Big Pharma Go here to watch... Dear Profit Alerts Member, The CBD industry has now entered uncharted market territory. As modern medicine makes its way out of the pharmaceutical industry and into this niche sector... It could offer incredible rewards for first movers. For those willing to take a look outside of Big Pharma's confines, a 10-fold opportunity could await. This singular event has created an opportunity like we've never seen before. And now, the CBD sector alone could grow more than 15 times faster than the entire cannabis industry as a whole. We're looking at an industry with the potential to grow by 3,622% in the coming year and a half. And here's the best part... Both of our top CBD picks are trading for under $4. These are companies that could return double-, triple-, even quadruple-digit gains practically overnight... So you'll want to make your move as quickly as possible. Find out how to get started here. Sincerely, Mike Ward Co-Founder, National Institute for Cannabis Investors To unsubscribe from Money Morning Profit Alerts emails click here. © 2019 Money Morning All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any recommendations in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 1125 N Charles Street, Baltimore MD 21201. To read our privacy policy click here. To contact Customer Service click here.